Background: The development of pharmacological interventions for perioperative complications, particularly spinal anesthesia-induced hypotension during cesarean section, faces substantial challenges including prolonged discovery timelines, high attrition rates, and limited translation of preclinical findings to clinical efficacy. Traditional drug development approaches require extensive time and financial investment, often spanning 10-15 years from initial target identification to regulatory approval. Ondansetron, a selective serotonin 5-HT3 receptor antagonist, exemplifies successful drug repurposing for preventing hypotension in obstetric anesthesia, yet its identification for this indication emerged through clinical observation rather than systematic screening approaches.  Aim: This article examines innovative strategies in pharmaceutical development that can accelerate therapeutic discovery and validation, with particular emphasis on high-throughput screening methodologies, computational target identification, and translational research frameworks applicable to perioperative medicine.  Discussion: Modern drug discovery increasingly leverages high-throughput screening platforms, structure-based drug design, and pharmacogenomic approaches to identify lead compounds with optimal therapeutic profiles. These strategies enable simultaneous evaluation of thousands of molecular entities against validated biological targets, dramatically reducing initial screening phases. Target identification and validation through genomic and proteomic technologies, combined with advanced preclinical modeling systems, facilitate more accurate prediction of clinical efficacy and safety profiles.  Impact: Implementation of these accelerated development strategies has demonstrated substantial reductions in discovery timelines and improved success rates in clinical translation, particularly for repurposed medications and precision medicine applications.  Perspective: Future advancement requires integration of artificial intelligence-driven prediction models, patient-specific precision medicine approaches, and adaptive clinical trial designs to further optimize therapeutic development for perioperative and obstetric applications.